The Effect of Metformin on Oncological Outcomes in Patients with Cervical Cancer with Type 2 Diabetes Mellitus

International Journal of Gynecological Cancer

Volumn 27, Issue 1, 2017, Pages 131-137

  Hanprasertpong, Jitti ^a   Jiamset, Ingporn ^a   Geater, Alan ^a   Peerawong, Thanarpan ^a   Hemman, Wikanda ^a   Kornsilp, Sasima ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Diabetes mellitus; Metformin; Prognosis; Uterine cervical neoplasms

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; COHORT ANALYSIS; DISEASE FREE SURVIVAL; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; UTERINE CERVIX CANCER; COMPLICATION; PATHOLOGY; UTERINE CERVIX TUMOR;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 85010028393     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000855     Document Type: Article

References (26)

1. Pimple S, Mishra G, Shastri S. Global strategies for cervicalcancer prevention. Curr Opin Obstet Gynecol. 2016;28:4-10.
2. Zhan YS, Feng L, Tang SH, et al. Glucose metabolism disordersin cancer patients in a Chinese population. Med Oncol.2010;27:177-184.
3. López-Hernández D. Type 2 diabetes mellitus and habitslifestyle increases the risk of cervical cancer: A cross-sectionalpopulation-based study. Austin J Obstet Gynecol. 2014;1:7.
4. Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level andcancer risk in Korean men and women. JAMA. 2005;293:194-202.
5. Kuo HY, Lin ZZ, Kuo R, et al. The prognostic impact of type 2diabetes mellitus on early cervical cancer in Asia. Oncologist.2015;20:1051-1057.
6. Jiamset I, Hanprasertpong J. Impact of diabetes mellitus ononcological outcomes after radical hysterectomy for early stagecervical cancer. J Gynecol Oncol. 2016;27:e28.
7. Febbraro T, Lengyel E, Romero IL. Old drug, new trick:repurposing metformin for gynecologic cancers? GynecolOncol. 2014;135:614-621.
8. Rojas LB, Gomes MB. Metformin: An old but still the besttreatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5:6.
9. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metforminand reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304-1305.
10. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancerrisk in diabetic patients: A systematic review and meta-analysis.Cancer Prev Res (Phila). 2010;3:1451-1461.
11. Sehdev A, Shih YC, Vekhter B, et al. Metformin for primarycolorectal cancer prevention in patients with diabetes: Acase-control study in a US population. Cancer. 2015;121:1071-1078.
12. Romero IL, McCormick A, McEwen KA, et al. Relationshipof type II diabetes and metformin use to ovarian cancerprogression, survival, and chemosensitivity. Obstet Gynecol.2012;119:61-67.
13. Ko EM,Walter P, Jackson A, et al. Metformin is associated withimproved survival in endometrial cancer. Gynecol Oncol.2014;132:438-442.
14. Xu H, Chen K, Jia X, et al. Metformin use is associatedwith better survival of breast cancer patients with diabetes: Ameta-analysis. Oncologist. 2015;20:1236-1244.
15. Kong F, Gao F, Liu H, et al. Metformin use improves the survivalof diabetic combined small-cell lung cancer patients. TumourBiol. 2015;36:8101-8106.
16. Tian RH, Zhang YG, Wu Z, et al. Effects of metformin onsurvival outcomes of lung cancer patients with type 2 diabetesmellitus: A meta-analysis. Clin Transl Oncol. 2016;18:641-649.
17. Rieken M, Xylinas E, Kluth L, et al. Diabetes mellitus withoutmetformin intake is associated with worse oncologic outcomesafter radical nephroureterectomy for upper tract urothelialcarcinoma. Eur J Surg Oncol. 2014;40:113-120.
18. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatmentwith the antidiabetic drug metformin selectively impairsp53-deficient tumor cell growth. Cancer Res. 2007;67:6745-6752.
19. Yung MM, Chan DW, Liu VW, et al. Activation of AMPKinhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascade. BMC Cancer. 2013;13:327.
20. Han K, Pintilie M, Lipscombe LL, et al. Association betweenmetformin use and mortality after cervical cancer in olderwomen with diabetes. Cancer Epidemiol Biomarkers Prev.2016;25:507-512.
21. Van De Voorde L, Janssen L, Larue R, et al. Can metforminimprove 'the tomorrow' of patients treated for oesophagealcancer? Eur J Surg Oncol. 2015;41:1333-1339.
22. Yu H, Yin L, Jiang X, et al. Effect of metformin on cancerrisk and treatment outcome of prostate cancer: A meta-analysisof epidemiological observational studies. PLoS One.2014;9:e116327.
23. Dilokthornsakul P, Chaiyakunapruk N, Termrungruanglert W,et al. The effects of metformin on ovarian cancer: A systematicreview. Int J Gynecol Cancer. 2013;23:1544-1551.
24. Xiao X, He Q, Lu C, et al. Metformin impairs the growth ofliver kinase B1-intact cervical cancer cells. Gynecol Oncol.2012;127:249-255.
25. Kwan HT, Chan DW, Cai PC, et al. AMPK activators suppresscervical cancer cell growth through inhibition of DVL3mediated Wnt/A-catenin signaling activity. PLoS One.2013;8:e53597.
26. Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecularmechanisms of metformin: An overview. Clin Sci (Lond).2012;122:253-270.